MDT

98.76

+1.94%↑

A

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

MDT

98.76

+1.94%↑

A

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

MDT

98.76

+1.94%↑

A

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

MDT

98.76

+1.94%↑

A

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

MDT

98.76

+1.94%↑

A

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

Search

Quidel Corp

Nyitva

34.89 4.43

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

33.23

Maximum

35.05

Fő mutatók

By Trading Economics

Munkavállalók

6,600

Ajánlások

By TipRanks

Ajánlások

Semleges

12 hónapos előrejelzés

-20.42% downside

Osztalékok

By Dow Jones

Következő eredményjelentés

2026. febr. 11.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

305M

1.9B

Előző nyitás

30.46

Előző zárás

34.89

Quidel Corp Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. jan. 14. 22:41 UTC

Felvásárlások, összeolvadások, átvételek

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

2026. jan. 15. 00:00 UTC

Eredményjelentés

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

2026. jan. 14. 23:47 UTC

Piaci beszéd

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

2026. jan. 14. 23:44 UTC

Piaci beszéd

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

2026. jan. 14. 23:39 UTC

Piaci beszéd

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

2026. jan. 14. 23:32 UTC

Piaci beszéd

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

2026. jan. 14. 22:56 UTC

Felvásárlások, összeolvadások, átvételek

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

2026. jan. 14. 22:53 UTC

Felvásárlások, összeolvadások, átvételek

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

2026. jan. 14. 22:17 UTC

Piaci beszéd

Global Equities Roundup: Market Talk

2026. jan. 14. 22:17 UTC

Piaci beszéd

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

2026. jan. 14. 22:09 UTC

Eredményjelentés

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

2026. jan. 14. 22:08 UTC

Eredményjelentés

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

2026. jan. 14. 22:08 UTC

Eredményjelentés

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

2026. jan. 14. 21:53 UTC

Felvásárlások, összeolvadások, átvételek

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

2026. jan. 14. 21:53 UTC

Felvásárlások, összeolvadások, átvételek

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

2026. jan. 14. 21:52 UTC

Felvásárlások, összeolvadások, átvételek

WuXi XDC Announces Positive Profit Alert for 2025

2026. jan. 14. 21:51 UTC

Felvásárlások, összeolvadások, átvételek

Citigroup Acting as Financial Advisor to WuXi XDC

2026. jan. 14. 21:51 UTC

Felvásárlások, összeolvadások, átvételek

WuXi XDC: Aims to Keep Listing Status of BioDlink

2026. jan. 14. 21:51 UTC

Felvásárlások, összeolvadások, átvételek

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

2026. jan. 14. 21:50 UTC

Piaci beszéd
Eredményjelentés

Financial Services Roundup: Market Talk

2026. jan. 14. 21:50 UTC

Piaci beszéd

Basic Materials Roundup: Market Talk

2026. jan. 14. 21:49 UTC

Felvásárlások, összeolvadások, átvételek

WuXi XDC: BioDlink Offer to Cost HK$2.79B

2026. jan. 14. 21:48 UTC

Felvásárlások, összeolvadások, átvételek

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

2026. jan. 14. 21:48 UTC

Felvásárlások, összeolvadások, átvételek

WuXi XDC Makes Cash Offer for BioDlink International

2026. jan. 14. 21:13 UTC

Piaci beszéd

Oil Retreats Late After Trump Comments on Iran -- Market Talk

2026. jan. 14. 20:30 UTC

Piaci beszéd
Eredményjelentés

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

2026. jan. 14. 20:13 UTC

Piaci beszéd

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

2026. jan. 14. 20:08 UTC

Piaci beszéd

Oil Futures Extend Rally on Iran Tensions -- Market Talk

2026. jan. 14. 19:33 UTC

Piaci beszéd

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

2026. jan. 14. 19:06 UTC

Piaci beszéd
Eredményjelentés

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Társak összehasonlítása

Árváltozás

Quidel Corp Előrejelzés

Célár

By TipRanks

-20.42% elmozdulás lefelé

12 hónapos előrejelzés

Átlag 26.5 USD  -20.42%

Magas 31 USD

Alacsony 22 USD

5 Wall Street elemző 12 hónapos célárain alapulva a(z)Quidel Corp termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

5 ratings

1

Vétel

3

Tartás

1

Eladás

Pénzügyek

$

Rólunk Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat